Apotex Moves First On Combigan As US Patent Expiry Looms
10 Orange Book Listed Patents Will Expire On 19 April
Apotex has moved first on Allergan’s Combigan, introducing a US authorized generic as the clock ticks on the originator’s IP. Sandoz is among ANDA sponsors seemingly waiting for patent protection to lapse.
You may also be interested in...
In the month ahead, Japanese firms are set to be hit with further price cuts to their generics, while Eagle Pharmaceuticals will throw off the restraints for its Pemfexy (pemetrexed) 505(b)(2) version of Eli Lilly’s Alimta.
Sandoz has gained a further advantage in its bid to introduce a generic of Allergan’s Combigan (brimonidine/timolol) 0.2%/0.5% eye drops in the US, following a favourable US Court of Appeals ruling.
Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of generic competition to its lucrative Vasostrict injectable led the firm to disclose potentially catastrophic Q2 profitability guidance.